Author:
Li Moying,Meindl-Beinker Nadja M.,Maenz Martin,Betge Johannes,Schulte Nadine,Zhan Tianzuo,Hofheinz Ralf-Dieter,Vogel Arndt,Angermeier Stefan,Bolling Claus,de Wit Maike,Jakobs Ralf,Karthaus Meinolf,Stocker Gertraud,Thuss-Patience Peter,Leidig Tobias,Bauer Hans,Ebert Matthias P.,Haertel Nicolai
Funder
Deutsche Forschungsgemeinschaft
Baden-Württemberg Stiftung
Bristol-Myers Squibb Co
Reference25 articles.
1. Oesophageal cancer;Lagergren;Lancet,2017
2. Esophageal cancer: a critical evaluation of systemic second-line therapy;Thallinger;J Clin Oncol,2011
3. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial;Kato;Lancet Oncol,2019
4. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study;Shen;J Clin Oncol,2022
5. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study;Huang;Lancet Oncol,2020